Latest Insider Transactions at Cerus Corp (CERS)
This section provides a real-time view of insider transactions for Cerus Corp (CERS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CERUS CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CERUS CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2022
|
Richard J Benjamin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,437
+13.31%
|
-
|
|
Mar 12
2022
|
Kevin Dennis Green Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
89,437
+9.68%
|
-
|
|
Mar 12
2022
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,437
+1.31%
|
-
|
|
Mar 12
2022
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
112,900
+9.39%
|
-
|
|
Mar 12
2022
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
320,695
+5.1%
|
-
|
|
Mar 04
2022
|
Jami K Nachtsheim Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,127
+10.05%
|
-
|
|
Mar 01
2022
|
Richard J Benjamin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+29.0%
|
-
|
|
Mar 01
2022
|
Laurence M Corash Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+2.13%
|
-
|
|
Mar 01
2022
|
Kevin Dennis Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+23.89%
|
-
|
|
Mar 01
2022
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+23.18%
|
-
|
|
Mar 01
2022
|
Chrystal Menard Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+30.3%
|
-
|
|
Mar 01
2022
|
Carol Moore SVP Reg. & Quality |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+16.46%
|
-
|
|
Mar 01
2022
|
William Mariner Greenman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
217,500
+10.72%
|
-
|
|
Feb 25
2022
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
308,263
-8.41%
|
$1,541,315
$5.71 P/Share
|
|
Feb 25
2022
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
380,000
+16.65%
|
$1,140,000
$3.75 P/Share
|
|
Jan 03
2022
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
19,059
-9.51%
|
$133,413
$7.0 P/Share
|
|
Jan 03
2022
|
Carol Moore SVP Reg. & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
19,059
+8.69%
|
$57,177
$3.66 P/Share
|
|
Dec 28
2021
|
Gail Schulze Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+25.36%
|
$75,000
$3.19 P/Share
|
|
Dec 17
2021
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+0.25%
|
$15,000
$3.75 P/Share
|
|
Dec 13
2021
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+1.94%
|
$120,000
$3.75 P/Share
|
|
Nov 09
2021
|
Gail Schulze Director |
SELL
Open market or private sale
|
Direct |
25,000
-47.07%
|
$175,000
$7.54 P/Share
|
|
Nov 09
2021
|
Gail Schulze Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+32.0%
|
$50,000
$2.86 P/Share
|
|
Nov 05
2021
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
110,000
-37.76%
|
$770,000
$7.94 P/Share
|
|
Nov 05
2021
|
Carol Moore SVP Reg. & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
110,000
+27.53%
|
$330,000
$3.75 P/Share
|
|
Nov 03
2021
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
165,000
-38.9%
|
$1,155,000
$7.53 P/Share
|
|
Nov 03
2021
|
Richard J Benjamin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
165,000
+27.44%
|
$660,000
$4.46 P/Share
|
|
Nov 03
2021
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
95,741
-20.63%
|
$670,187
$7.0 P/Share
|
|
Nov 03
2021
|
Kevin Dennis Green Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
95,000
+27.64%
|
$285,000
$3.75 P/Share
|
|
Nov 03
2021
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
40,000
-37.37%
|
$280,000
$7.7 P/Share
|
|
Sep 05
2021
|
Timothy L. Moore Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,296
+8.78%
|
-
|
|
Aug 06
2021
|
Ann Lucena Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,784
+50.0%
|
-
|
|
Aug 04
2021
|
Daniel N Swisher Jr Director |
SELL
Open market or private sale
|
Direct |
12,877
-12.12%
|
$77,262
$6.25 P/Share
|
|
Aug 04
2021
|
Daniel N Swisher Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,877
+10.81%
|
$25,754
$2.86 P/Share
|
|
Aug 03
2021
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+6.18%
|
$200,000
$2.08 P/Share
|
|
Jun 02
2021
|
Eric Bjerkholt Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,888
+20.8%
|
-
|
|
Jun 02
2021
|
Timothy L. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,888
+26.97%
|
-
|
|
Jun 02
2021
|
Jami K Nachtsheim Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,888
+26.74%
|
-
|
|
Jun 02
2021
|
Gail Schulze Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,888
+34.62%
|
-
|
|
Jun 02
2021
|
Frank Witney Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,888
+13.0%
|
-
|
|
Jun 02
2021
|
Daniel N Swisher Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,525
+15.81%
|
-
|
|
Jun 01
2021
|
Timothy B Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,228
+5.82%
|
-
|
|
Jun 01
2021
|
Eric Bjerkholt Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,228
+24.04%
|
-
|
|
Jun 01
2021
|
Timothy L. Moore Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,228
+34.21%
|
-
|
|
Jun 01
2021
|
Jami K Nachtsheim Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,228
+33.81%
|
-
|
|
Jun 01
2021
|
Gail Schulze Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,228
+50.0%
|
-
|
|
Jun 01
2021
|
Frank Witney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,228
+13.51%
|
-
|
|
Jun 01
2021
|
Daniel N Swisher Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,961
+17.39%
|
-
|
|
May 18
2021
|
Daniel N Swisher Jr Director |
SELL
Open market or private sale
|
Direct |
5,000
-7.71%
|
$25,000
$5.75 P/Share
|
|
May 18
2021
|
Daniel N Swisher Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.16%
|
$10,000
$2.9 P/Share
|
|
Apr 30
2021
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,200
+1.26%
|
$75,600
$3.66 P/Share
|